ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
Share price
−$0.3642 (−59.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ELITE PHARMACEUTICALS INC /NV/ grew revenue 33.7% to $141.01M over the twelve months to Jun 30, 2026. Operating income fell 6.7% to $34.94M, moving the operating margin from 35.5% to 24.8%. Free cash flow was $17.53M, down 2.8% from a year earlier.
Revenue
$141.01M
+33.7% vs. a year earlier
Operating income
$34.94M
-6.7% vs. a year earlier
Free cash flow
$17.53M
-2.8% vs. a year earlier
EPS, diluted
$0.05
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $283.02M
- P/E ratio
- 5.0
- Price to sales
- 2.01
- Price to book
- 2.70
- Dividend yield
- –
- Free cash flow yield
- 6.19%
Fundamentals
- Revenue
- $141.01M
- Net income
- $56.67M
- EPS, diluted
- $0.05
- Free cash flow
- $17.53M
- Book value per share
- $0.09
- Diluted shares
- 1.13B
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$141.01M+33.7% YoY
Gross profit
$61.31M+4.2% YoY
Operating income
$34.94M-6.7% YoY
Net income
$56.67M
EPS, diluted
$0.05
Free cash flow
$17.53M-2.8% YoY
Reported periodTrailing twelve months